Business
Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
- Clinical data highlight potential utility of T cell clonality as a predictive and prognost...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019- Clinical data highlight potential utility of T cell clonality as a predictive and prognostic biomarker of pelareorep therapy -- Using pelareorep in advance of the checkpoint inhibitor Keytruda® safely primes the immune system to target cancer cells in pancreatic cancer patients -CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 which is taking place March 30 through April 3 in Atlanta, Georgia.The poster, entitled, \"Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma,\" describes analysis of patient samples from REO 024; a study of pelareorep and Keytruda® in combination with chemotherapy in patients with advanced (second-line) pancreatic cancer.\"We are thrilled with the rates of disease control observed in this study evaluating pelareorep and Keytruda in combination with chemotherapy in patients with advanced second-line pancreatic cancer,\" said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. \"The data presented at AACR now demonstrate that the degree of T cell clonality, examined in patients from REO 024, has the potential to serve as a predictive and prognostic biomarker of pelareorep therapy. Providing physicians with a simple blood test to understand which patients are likely to respond to treatment is invaluable, allowing the medical community to target the right treatment to the right patient. We look forward to utilizing this new biomarker as we move forward with all of our current clinical programs with checkpoint inhibitors including trials for multiple myeloma, our ongoing phase 2 second-line pancreatic cancer study, and of course, our breast cancer program.\"Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech, said, \"These data provide additional insight into the underlying biology that drives the efficacy of pel...